This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- CYC-065
- DrugBank Accession Number
- DB15425
- Background
CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for CYC-065 (DB15425)
- Weight
- Average: 397.527
Monoisotopic: 397.259008646 - Chemical Formula
- C21H31N7O
- Synonyms
- Not Available
- External IDs
- CYC065
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- YET2XNU791
- CAS number
- 1070790-89-4
- InChI Key
- DLPIYBKBHMZCJI-WBVHZDCISA-N
- InChI
- InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1
- IUPAC Name
- (2R,3S)-3-[(6-{[(4,6-dimethylpyridin-3-yl)methyl]amino}-9-(propan-2-yl)-9H-purin-2-yl)amino]pentan-2-ol
- SMILES
- CC[C@H](NC1=NC(NCC2=C(C)C=C(C)N=C2)=C2N=CN(C(C)C)C2=N1)[C@@H](C)O
References
- General References
- Not Available
- External Links
- ChemSpider
- 34957698
- BindingDB
- 106950
- ChEMBL
- CHEMBL3655762
- ZINC
- ZINC000096177788
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Active Not Recruiting Treatment Acute Myeloid Leukemia / Myelodysplastic Syndrome 1 1 Active Not Recruiting Treatment Cancer 1 1 Active Not Recruiting Treatment Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) 1 1, 2 Recruiting Treatment Adult Solid Tumor / Lymphoma 1 1, 2 Recruiting Treatment Leukemias / Myelodysplastic Syndrome 1 1, 2 Recruiting Treatment Pediatric Cancer 1 0 Active Not Recruiting Treatment Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0598 mg/mL ALOGPS logP 3.1 ALOGPS logP 2.74 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 14.2 Chemaxon pKa (Strongest Basic) 6.36 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 100.78 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 118.04 m3·mol-1 Chemaxon Polarizability 45.53 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 15:28 / Updated at June 12, 2020 16:53